|Biotech Due Diligence||
A double-dose of journal articles that have been making the rounds on Twitter and driving the investment conversation recently. Thanks to all for the education, engagement and community throughout 2017!
Innovation and growth abound for BSX, EW, JNJ, and SYK! Also, a great overview of EW plans for 2018 and a discussion of the impact of the corporate tax rate cut on medical device companies. All this and more from this week's Medical Device Reading List.
Boston Scientific ($BSX) continues to struggle after a Q1 product recall, while Edwards ($EW) and Medtronic ($MDT) are moving forward with product pipelines and hurricane recovery updates.
Boston Scientific (BSX) Shares Drop on LOTUS Relaunch Delay
Why Boston Scientific Needs to Innovate
Edwards Lifesciences' Pipeline Strong Amid Rising Expenses
Medtronic (MDT) Tops Q2 EPS by 8c, Reiterates Guidance
Medtronic Announces FDA Approval and U.S. Launch of Next Generation Pacemakers
Press Release ($MDT)
Embracing Medtronic After Hurricane Maria
Seeking Alpha ($MDT)